BeiGene Ltd

BGNE

Equity

ISIN US07725L1026 / Valor 30165310

NASDAQ (2024-09-17)

USD 197.51+0.54%

BeiGene Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

BeiGene Ltd is a publicly traded global oncology company with a market capitalization of approximately $23 billion and a global workforce of over 10,000 employees. The company has a presence in Asia, Australia, Europe, Latin America, and North America, with administrative offices in Basel, Beijing, and Cambridge, Mass. BeiGene is known for its growing portfolio of oncology treatments in various stages of development, with a focus on innovative and accessible medicines for cancer patients worldwide. The company collaborates with biopharmaceutical companies to develop and commercialize cancer therapies, and has a strong research team working on a broad pipeline of potential treatments. One of BeiGene's key products is BRUKINSA, a small molecule inhibitor of Bruton’s tyrosine kinase, approved for the treatment of various B-cell malignancies in 70 markets globally. Co-founded by John V. Oyler in 2010, BeiGene is dedicated to addressing a wide range of cancers and making a positive impact in the field of oncology.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue

BeiGene Ltd reported total revenue of $752 million for the first quarter of 2024, a significant increase from $448 million in the same period of 2023. This growth was primarily driven by the substantial rise in BRUKINSA product sales in the U.S. and Europe, which saw increases of 153% and 243% respectively.

Product Revenue

Product revenue for BeiGene Ltd in the first quarter of 2024 was $747 million, compared to $410 million in the same period of 2023, representing an 82% increase. This surge in product revenue was mainly due to the increased sales of the company's internally developed products, BRUKINSA and tislelizumab.

U.S. Market Performance

For the three months ended March 31, 2024, the U.S. was BeiGene Ltd's largest market, with product revenue of $351 million. This is a substantial increase from $139 million in the prior-year period, highlighting the strong performance and market penetration of BRUKINSA in the U.S.

Gross Margin

BeiGene Ltd's gross margin as a percentage of global product revenue for the first quarter of 2024 was 83%, compared to 80% in the prior-year period. The increase in gross margin percentage was primarily due to a higher sales mix of global BRUKINSA.

Net Revenue from Collaborations

Net revenue from collaborations for BeiGene Ltd in the first quarter of 2024 was $4.7 million, a significant decrease from $37.5 million in the same period of 2023. This 87% decline reflects changes in the company's collaboration agreements and revenue recognition.

Summarized from source with an LLMView Source

Key figures

-1.40%1Y

-51.0%3Y

48.4%5Y

Performance

46.6%1Y

60.9%3Y

59.4%5Y

Volatility